Hepatitis B Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who come from a family where hepatitis B virus (HBV) infection has occurred across two generations of blood relatives, and where at least one person in two or more generations has developed cirrhosis (liver scarring) or liver cancer linked to HBV
- People who have been testing positive for the hepatitis B surface antigen (a marker of HBV infection) for more than 6 months, AND who are either currently being treated with a specific type of antiviral medication for hepatitis B, OR have compensated cirrhosis (a form of liver scarring where the liver is still functioning) caused by hepatitis B
- Women of childbearing age who have had a negative pregnancy test within 24 hours before the first dose of the study medication (for those in the treatment group)
- People who have no medical reasons preventing them from receiving interferon treatment
Who may not be able to join:
- People who have already been diagnosed with liver cancer or any other cancer before the start of treatment
- People who have medical reasons that prevent them from taking the medication Peg IFN α-2b (confirm with trial site for the full list of these reasons)
- People whose blood cell counts fall below certain levels — specifically, white blood cells below 3.0 × 10⁹/L or platelets below 70 × 10⁹/L (confirm with trial site)
- People whose liver function test results are significantly above the normal range — specifically, ALT more than 5 times the upper limit of normal, or total bilirubin more than 2 times the upper limit of normal
- People who are planning to have an organ transplant or who have already had one
- People who have a known allergy to interferon or any other reason listed in the product information that would make it unsuitable for them
- People where the trial doctor considers there to be any other reason that makes participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yingren Zhao, Professor, First Affiliated Hospital of Xian Jiaotong University
Phone: 0086-029-85323437
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
the number and percentage of cases of cirrhosis and HCC occurring in the non-cirrhosis population; the number and percentage of cases of decompensated cirrhosis and HCC occurring in the compensated cirrhosis population
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.